Literature DB >> 17650443

Trisomy 13 correlates with RUNX1 mutation and increased FLT3 expression in AML-M0 patients.

Fernando P G Silva1, Alexandra Lind, Geeske Brouwer-Mandema, Peter J M Valk, Micheline Giphart-Gassler.   

Abstract

Of 52 AML-M0 patients studied, 16 presented a RUNX1 mutation (30.8 %) and 8 carried a trisomy 13 (15 %). We found a strong correlation between trisomy 13 and RUNX1 mutations, i.e, 7 out of 8 cases with trisomy 13 carried a mutation in RUNX1 (87.5 %, p<0.00056). Trisomy 13 patients with a RUNX1 mutation showed a 4-fold higher expression of FLT3 mRNA compared to controls, and in a selected number of cases, a higher cell fraction expressing FLT3 and an increase in the number of FLT3 receptors at the cell surface. In conclusion, our results show that trisomy 13 is correlated to RUNX1 mutation and increased FLT3 expression in AML-M0.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17650443     DOI: 10.3324/haematol.11296

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  15 in total

1.  Myelodysplastic Syndrome with concomitant t(5;21)(q15;q22) and del(5)(q13q33): case report and review of literature.

Authors:  Anup Kasi Loknath Kumar; Brandon Weckbaugh; Christopher Sirridge; Janet Woodroof; Diane Persons; Suman Kambhampati
Journal:  Stem Cell Investig       Date:  2016-02-23

2.  Clinical and molecular characterization of patients with acute myeloid leukemia and sole trisomies of chromosomes 4, 8, 11, 13 or 21.

Authors:  Bhavana Bhatnagar; Ann-Kathrin Eisfeld; Jessica Kohlschmidt; Krzysztof Mrózek; Deedra Nicolet; Dimitrios Papaioannou; Christopher J Walker; Shelley Orwick; James S Blachly; Jonathan E Kolitz; Bayard L Powell; Andrew J Carroll; Richard M Stone; John C Byrd; Clara D Bloomfield
Journal:  Leukemia       Date:  2019-08-28       Impact factor: 11.528

3.  TdT expression in acute myeloid leukemia with minimal differentiation is associated with distinctive clinicopathological features and better overall survival following stem cell transplantation.

Authors:  Keyur P Patel; Faisal A Khokhar; Tariq Muzzafar; M James You; Carlos E Bueso-Ramos; Farhad Ravandi; Sherrie Pierce; L Jeffrey Medeiros
Journal:  Mod Pathol       Date:  2012-08-31       Impact factor: 7.842

4.  RUNX1 mutations in cytogenetically normal acute myeloid leukemia are associated with a poor prognosis and up-regulation of lymphoid genes.

Authors:  Philipp A Greif; Nikola P Konstandin; Klaus H Metzeler; Tobias Herold; Zlatana Pasalic; Bianka Ksienzyk; Annika Dufour; Friederike Schneider; Stephanie Schneider; Purvi M Kakadia; Jan Braess; Maria Cristina Sauerland; Wolfgang E Berdel; Thomas Büchner; Bernhard J Woermann; Wolfgang Hiddemann; Karsten Spiekermann; Stefan K Bohlander
Journal:  Haematologica       Date:  2012-06-11       Impact factor: 9.941

5.  Truncated RUNX1 protein generated by a novel t(1;21)(p32;q22) chromosomal translocation impairs the proliferation and differentiation of human hematopoietic progenitors.

Authors:  S Rodriguez-Perales; R Torres-Ruiz; J Suela; F Acquadro; M C Martin; E Yebra; J C Ramirez; S Alvarez; J C Cigudosa
Journal:  Oncogene       Date:  2015-03-23       Impact factor: 9.867

6.  RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.

Authors:  Jason H Mendler; Kati Maharry; Michael D Radmacher; Krzysztof Mrózek; Heiko Becker; Klaus H Metzeler; Sebastian Schwind; Susan P Whitman; Jihane Khalife; Jessica Kohlschmidt; Deedra Nicolet; Bayard L Powell; Thomas H Carter; Meir Wetzler; Joseph O Moore; Jonathan E Kolitz; Maria R Baer; Andrew J Carroll; Richard A Larson; Michael A Caligiuri; Guido Marcucci; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2012-07-02       Impact factor: 44.544

7.  Genome wide molecular analysis of minimally differentiated acute myeloid leukemia.

Authors:  Fernando P G Silva; Inês Almeida; Bruno Morolli; Geeske Brouwer-Mandema; Hans Wessels; Rolf Vossen; Harry Vrieling; Erik W A Marijt; Peter J M Valk; Hanneke C Kluin-Nelemans; Wolfgang R Sperr; Wolf-Dieter Ludwig; Micheline Giphart-Gassler
Journal:  Haematologica       Date:  2009-09-22       Impact factor: 9.941

8.  Modeling interactions between leukemia-specific chromosomal changes, somatic mutations, and gene expression patterns during progression of core-binding factor leukemias.

Authors:  Dan Jones; Hui Yao; Angela Romans; Caroline Dando; Sherry Pierce; Gautam Borthakur; Amy Hamilton; Carlos Bueso-Ramos; Farhad Ravandi; Guillermo Garcia-Manero; Hagop Kantarjian
Journal:  Genes Chromosomes Cancer       Date:  2010-02       Impact factor: 5.006

9.  Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13.

Authors:  Todd A Fehniger; John C Byrd; Guido Marcucci; Camille N Abboud; Cheryl Kefauver; Jacqueline E Payton; Ravi Vij; William Blum
Journal:  Blood       Date:  2008-09-29       Impact factor: 22.113

10.  FLT3 expression and IL10 promoter polymorphism in acute myeloid leukemia with RUNX1-RUNX1T1.

Authors:  Myungshin Kim; Jiyeon Kim; Jung Rok Kim; Eunhee Han; Joonhong Park; Jihyang Lim; Yonggoo Kim; Kyungja Han; Hee-Je Kim; Woo-Sung Min; Bin Cho
Journal:  Mol Biol Rep       Date:  2014-10-07       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.